Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY4405094
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
LY4405094 is a small interfering RNA (siRNA) therapeutic developed by Eli Lilly for the treatment of Alzheimer's disease. It is designed to target the mRNA of the microtubule-associated protein tau (MAPT) gene, leading to its degradation and a subsequent reduction in the production of tau protein. The accumulation of hyperphosphorylated tau into neurofibrillary tangles is a core pathological feature of Alzheimer's disease and is strongly correlated with neurodegeneration and cognitive impairment. By silencing MAPT expression, LY4405094 aims to slow or halt disease progression. The drug is administered via intrathecal injection and is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacodynamic effects on tau levels in healthy participants and individuals with Alzheimer's disease.
- Other names
- Tau siRNA
02
Targets
MAPT (Microtubule-associated protein tau)
Beyond the preview
Go deeper on LY4405094.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY4405094.